A Multicenter, Randomized, Parallel-controlled Clinical Trial Protocol to Validate the Safety and Efficacy of a Steep Pulse Therapy System for the Treatment of Liver Tumors

Exclusion Criteria

• •1. It is less than 30 days after the end of chemotherapy, radiotherapy, immunotherapy, or targeted therapy.
• •2. Within 3 months after ablation, patients need to continue treatment with chemotherapy, radiation therapy, immunotherapy, targeted therapy, surgery, or other minimally invasive modalities.
• •3. patients with severe infectious diseases such as bacteremia and toxemia.
• •4. patients with uncorrectable coagulation dysfunction (PLT\<40xl09/L).
• •5. patients with severe heart, brain, lung and other diseases, and patients with severe arrhythmia.
• •6. patients with implanted artificial hearts, lungs, internal pulse regulators or wearable medical electronic devices such as electrocardiography.
• •7. Patients with a history of epilepsy.
• •8. Patients with acute myocardial infarction within 6 months.
• •9. Pregnant and lactating women and those who plan to become pregnant within one year.
• •10. Those who are allergic to ultrasound, CT or MRI contrast agents.
• •11. Those who are contraindicated in general anesthesia.
• •12. Those who have participated in clinical trials of any drug or medical device within the first 3 months of the group.
• •13. The researchers believe that there are other factors that are not suitable for inclusion or that affect the participation of subjects in the study.